Need for a paradigm shift in therapeutic approaches to CNS injury

References

• Kelley KW, Johnson RW, Dantzer R. Immunology discovers physiology. Vet Immunol. Immunopathol.43(1–3), 157–165 (1994).
   PubMedGoogle Scholar
• Lawson LJ, Perry VH, Dri P, Gordon S. Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience39(1), 151–170 (1990).
   PubMed Web of Science ®Google Scholar
• Sievers J, Parwaresch R, Wottge HU. Blood monocytes and spleen macrophages differentiate into microglia-like cells on monolayers of astrocytes: morphology. Glia12(4), 245–258 (1994).
   PubMed Web of Science ®Google Scholar
• Kitamura T, Miyake T, Fujita S. Genesis of resting microglia in the gray matter of mouse hippocampus. J. Comp. Neurol.226(3), 421–433 (1984).
   PubMed Web of Science ®Google Scholar
• Schelper RL, Adrian EK Jr. Non-specific esterase activity in reactive cells in injured nervous tissue labeled with 3H-thymidine or 125iododeoxyuridine injected before injury. J. Comp. Neurol.194(4), 829–844 (1980).
   PubMedGoogle Scholar
• Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science308(5726), 1314–1318 (2005).
   PubMed Web of Science ®Google Scholar
• Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat. Rev. Neurosci.8(1), 57–69 (2007).
   PubMed Web of Science ®Google Scholar
• Butovsky O, Talpalar AE, Ben-Yaakov K, Schwartz M. Activation of microglia by aggregated β-amyloid or lipopolysaccharide impairs MHC-II expression and renders them cytotoxic whereas IFN-γ and IL-4 render them protective. Mol. Cell Neurosci.29(3), 381–393 (2005).
   PubMedGoogle Scholar
• Hanisch UK, Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat. Neurosci.10(11), 1387–1394 (2007).
   PubMed Web of Science ®Google Scholar
• Barres BA. The mystery and magic of glia: a perspective on their roles in health and disease. Neuron60(3), 430–440 (2008).
   PubMed Web of Science ®Google Scholar
• McDonald JW, Sadowsky C. Spinal-cord injury. Lancet359(9304), 417–425 (2002).
   PubMed Web of Science ®Google Scholar
• Iadecola C, Anrather J. The immunology of stroke: from mechanisms to translation. Nat. Med.17(7), 796–808 (2011).
   PubMed Web of Science ®Google Scholar
• Larner AJ, Doran M. Clinical phenotypic heterogeneity of Alzheimer’s disease associated with mutations of the presenilin-1 gene. J. Neurol.253(2), 139–158 (2006).
   PubMed Web of Science ®Google Scholar
• Obulesu M, Venu R, Somashekhar R. Tau mediated neurodegeneration: an insight into Alzheimer’s disease pathology. Neurochem. Res.36(8), 1329–1335 (2011).
   PubMed Web of Science ®Google Scholar
• Gurney ME, Liu R, Althaus JS, Hall ED, Becker DA. Mutant CuZn superoxide dismutase in motor neuron disease. J. Inherit. Metab. Dis.21(5), 587–597 (1998).
   PubMed Web of Science ®Google Scholar
• Morrison BM, Morrison JH. Amyotrophic lateral sclerosis associated with mutations in superoxide dismutase: a putative mechanism of degeneration. Brain Res. Rev.29(1), 121–135 (1999).
   PubMedGoogle Scholar
• Siddique T, Nijhawan D, Hentati A. Familial amyotrophic lateral sclerosis. J. Neural. Transm. Suppl.49, 219–233 (1997).
   PubMedGoogle Scholar
• Cluskey S, Ramsden DB. Mechanisms of neurodegeneration in amyotrophic lateral sclerosis. Mol. Pathol.54(6), 386–392 (2001).
   PubMedGoogle Scholar
• Neumann M, Sampathu DM, Kwong LK et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science314(5796), 130–133 (2006).
   PubMed Web of Science ®Google Scholar
• Valdmanis PN, Daoud H, Dion PA, Rouleau GA. Recent advances in the genetics of amyotrophic lateral sclerosis. Curr. Neurol. Neurosci. Rep.9(3), 198–205 (2009).
   PubMed Web of Science ®Google Scholar
• Stewart H, Rutherford NJ, Briemberg H et al. Clinical and pathological features of amyotrophic lateral sclerosis caused by mutation in the C9ORF72 gene on chromosome 9p. Acta Neuropathol.123(3), 409–417 (2012).
   PubMed Web of Science ®Google Scholar
• Kurtzke JF, Hyllested K. Multiple sclerosis in the Faroe Islands and the lack of protection by exposure in infancy. Neuroepidemiology11(2), 90–99 (1992).
   PubMedGoogle Scholar
• Orton SM, Herrera BM, Yee IM et al. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol.5(11), 932–936 (2006).
   PubMed Web of Science ®Google Scholar
• Wallin MT, Page WF, Kurtzke JF. Multiple sclerosis in US veterans of the Vietnam era and later military service: race, sex, and geography. Ann. Neurol.55(1), 65–71 (2004).
   PubMed Web of Science ®Google Scholar
• Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N. Engl. J. Med.343(13), 938–952 (2000).
   PubMed Web of Science ®Google Scholar
• Weinshenker BG, Bass B, Rice GP et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain112(Pt 1), 133–146 (1989).
   PubMed Web of Science ®Google Scholar
• Hagg T, Oudega M. Degenerative and spontaneous regenerative processes after spinal cord injury. J. Neurotrauma.23(3–4), 264–280 (2006).
   PubMed Web of Science ®Google Scholar
• Silver J, Miller JH. Regeneration beyond the glial scar. Nat. Rev. Neurosci.5(2), 146–156 (2004).
   PubMed Web of Science ®Google Scholar
• Fitch MT, Doller C, Combs CK, Landreth GE, Silver J. Cellular and molecular mechanisms of glial scarring and progressive cavitation: in vivo and in vitro analysis of inflammation-induced secondary injury after CNS trauma. J. Neurosci.19(19), 8182–8198 (1999).
   PubMed Web of Science ®Google Scholar
• Leal-Filho MB. Spinal cord injury: from inflammation to glial scar. Surg. Neurol. Int.2, 112 (2011).
   PubMedGoogle Scholar
• Zhang H, Muramatsu T, Murase A, Yuasa S, Uchimura K, Kadomatsu K. N-acetylglucosamine 6-O-sulfotransferase-1 is required for brain keratan sulfate biosynthesis and glial scar formation after brain injury. Glycobiology16(8), 702–710 (2006).
   PubMedGoogle Scholar
• Lo EH. A new penumbra: transitioning from injury into repair after stroke. Nat. Med.14(5), 497–500 (2008).
   PubMed Web of Science ®Google Scholar
• LaFerla FM, Green KN, Oddo S. Intracellular amyloid-β in Alzheimer’s disease. Nat. Rev. Neurosci.8(7), 499–509 (2007).
   PubMed Web of Science ®Google Scholar
• Abe N, Cavalli V. Nerve injury signaling. Curr. Opin. Neurobiol.18(3), 276–283 (2008).
   PubMed Web of Science ®Google Scholar
• David S, Aguayo AJ. Axonal elongation into peripheral nervous system “bridges” after central nervous system injury in adult rats. Science214(4523), 931–933 (1981).
   PubMed Web of Science ®Google Scholar
• Fitch MT, Silver J. CNS injury, glial scars, and inflammation: Inhibitory extracellular matrices and regeneration failure. Exp. Neurol.209(2), 294–301 (2008).
   PubMed Web of Science ®Google Scholar
• Yiu G, He Z. Glial inhibition of CNS axon regeneration. Nat. Rev. Neurosci.7(8), 617–627 (2006).
   PubMed Web of Science ®Google Scholar
• Benson MD, Romero MI, Lush ME, Lu QR, Henkemeyer M, Parada LF. Ephrin-B3 is a myelin-based inhibitor of neurite outgrowth. Proc. Natl Acad. Sci. USA102(30), 10694–10699 (2005).
   PubMed Web of Science ®Google Scholar
• Lee JK, Geoffroy CG, Chan AF et al. Assessing spinal axon regeneration and sprouting in Nogo-, MAG-, and OMgp-deficient mice. Neuron66(5), 663–670 (2010).
   PubMed Web of Science ®Google Scholar
• Shen Y, Tenney AP, Busch SA et al. PTPσ is a receptor for chondroitin sulfate proteoglycan, an inhibitor of neural regeneration. Science326(5952), 592–596 (2009).
   PubMed Web of Science ®Google Scholar
• Zheng B, Atwal J, Ho C et al. Genetic deletion of the Nogo receptor does not reduce neurite inhibition in vitro or promote corticospinal tract regeneration in vivo. Proc. Natl Acad. Sci. USA102(4), 1205–1210 (2005).
   PubMed Web of Science ®Google Scholar
• Lobato RD. Historical vignette of Cajal’s work ‘Degeneration and regeneration of the nervous system’ with a reflection of the author. Neurocirugia (Astur.)19(5), 456–468 (2008).
   PubMedGoogle Scholar
• Tom VJ, Steinmetz MP, Miller JH, Doller CM, Silver J. Studies on the development and behavior of the dystrophic growth cone, the hallmark of regeneration failure, in an in vitro model of the glial scar and after spinal cord injury. J. Neurosci.24(29), 6531–6539 (2004).
   PubMed Web of Science ®Google Scholar
• Hur EM, Yang IH, Kim DH et al. Engineering neuronal growth cones to promote axon regeneration over inhibitory molecules. Proc. Natl Acad. Sci. USA108(12), 5057–5062 (2011).
   PubMed Web of Science ®Google Scholar
• Davies SJ, Fitch MT, Memberg SP, Hall AK, Raisman G, Silver J. Regeneration of adult axons in white matter tracts of the central nervous system. Nature390(6661), 680–683 (1997).
   PubMed Web of Science ®Google Scholar
• Davies SJ, Goucher DR, Doller C, Silver J. Robust regeneration of adult sensory axons in degenerating white matter of the adult rat spinal cord. J. Neurosci.19(14), 5810–5822 (1999).
   PubMed Web of Science ®Google Scholar
• Cai D, Deng K, Mellado W, Lee J, Ratan RR, Filbin MT. Arginase I and polyamines act downstream from cyclic AMP in overcoming inhibition of axonal growth MAG and myelin in vitro. Neuron35(4), 711–719 (2002).
   PubMed Web of Science ®Google Scholar
• Schmidt S, Haase CG, Bezman L et al. Serum autoantibody responses to myelin oligodendrocyte glycoprotein and myelin basic protein in X-linked adrenoleukodystrophy and multiple sclerosis. J. Neuroimmunol.119(1), 88–94 (2001).
   PubMedGoogle Scholar
• Karni A, Bakimer-Kleiner R, Abramsky O, Ben-Nun A. Elevated levels of antibody to myelin oligodendrocyte glycoprotein is not specific for patients with multiple sclerosis. Arch. Neurol.56(3), 311–315 (1999).
   PubMedGoogle Scholar
• Endo T, Scott DD, Stewart SS, Kundu SK, Marcus DM. Antibodies to glycosphingolipids in patients with multiple sclerosis and SLE. J. Immunol.132(4), 1793–1797 (1984).
   PubMedGoogle Scholar
• Freedman MS, Laks J, Dotan N, Altstock RT, Dukler A, Sindic CJ. Anti-α-glucose-based glycan IgM antibodies predict relapse activity in multiple sclerosis after the first neurological event. Mult. Scler.15(4), 422–430 (2009).
   PubMed Web of Science ®Google Scholar
• Schwarz M, Spector L, Gortler M et al. Serum anti-Glc(α1,4)Glc(α) antibodies as a biomarker for relapsing-remitting multiple sclerosis. J. Neurol. Sci.244(1–2), 59–68 (2006).
   PubMed Web of Science ®Google Scholar
• Bornstein NM, Aronovich B, Korczyn AD, Shavit S, Michaelson DM, Chapman J. Antibodies to brain antigens following stroke. Neurology56(4), 529–530 (2001).
   PubMedGoogle Scholar
• Dambinova SA, Khounteev GA, Izykenova GA, Zavolokov IG, Ilyukhina AY, Skoromets AA. Blood test detecting autoantibodies to N-methyl-D-aspartate neuroreceptors for evaluation of patients with transient ischemic attack and stroke. Clin. Chem.49(10), 1752–1762 (2003).
   PubMed Web of Science ®Google Scholar
• Davies AL, Hayes KC, Dekaban GA. Clinical correlates of elevated serum concentrations of cytokines and autoantibodies in patients with spinal cord injury. Arch. Phys. Med. Rehabil.88(11), 1384–1393 (2007).
   PubMed Web of Science ®Google Scholar
• Hayes KC, Hull TC, Delaney GA et al. Elevated serum titers of proinflammatory cytokines and CNS autoantibodies in patients with chronic spinal cord injury. J. Neurotrauma19(6), 753–761 (2002).
   PubMed Web of Science ®Google Scholar
• Stefan J, Prochazka M, Voltnerova M. Studies of immunologic reactions after brain injury. I. Antibodies against brain tissue lipids after experimental injury of the brain in rabbits. Int. Surg.55(5), 316–321 (1971).
   PubMedGoogle Scholar
• Skoda D, Kranda K, Bojar M et al. Antibody formation against β-tubulin Class 3 in response to brain trauma. Brain Res. Bull.68(4), 213–216 (2006).
   PubMed Web of Science ®Google Scholar
• Ponomarenko NA, Durova OM, Vorobiev II et al. Autoantibodies to myelin basic protein catalyze site-specific degradation of their antigen. Proc. Natl Acad. Sci. USA103(2), 281–286 (2006).
   PubMed Web of Science ®Google Scholar
• Ponomarenko NA, Durova OM, Vorobiev II et al. Catalytic activity of autoantibodies toward myelin basic protein correlates with the scores on the multiple sclerosis expanded disability status scale. Immunol. Lett.103(1), 45–50 (2006).
   PubMed Web of Science ®Google Scholar
• Taguchi H, Planque S, Nishiyama Y et al. Autoantibody-catalyzed hydrolysis of amyloid β peptide. J. Biol. Chem.283(8), 4714–4722 (2008).
   PubMed Web of Science ®Google Scholar
• Lacroix-Desmazes S, Moreau A, Sooryanarayana et al. Catalytic activity of antibodies against factor VIII in patients with hemophilia A. Nat. Med.5(9), 1044–1047 (1999).
   PubMed Web of Science ®Google Scholar
• Wootla B, Christophe OD, Mahendra A et al. Proteolytic antibodies activate factor IX in patients with acquired hemophilia. Blood117(7), 2257–2264 (2011).
   PubMedGoogle Scholar
• Wootla B, Dasgupta S, Dimitrov JD et al. Factor VIII hydrolysis mediated by anti-factor VIII autoantibodies in acquired hemophilia. J. Immunol.180(11), 7714–7720 (2008).
   PubMed Web of Science ®Google Scholar
• Lacroix-Desmazes S, Bayry J, Kaveri SV et al. High levels of catalytic antibodies correlate with favorable outcome in sepsis. Proc. Natl Acad. Sci. USA102(11), 4109–4113 (2005).
   PubMedGoogle Scholar
• Thiagarajan P, Dannenbring R, Matssura K, Tramontano A, Gololobov G, Paul S. Monoclonal antibody light chain with prothrombinase activity. Biochemistry39, 6459–6465 (2000).
   PubMedGoogle Scholar
• Wootla B, Nicoletti A, Patey N et al. Hydrolysis of coagulation factors by circulating IgG is associated with a reduced risk for chronic allograft nephropathy in renal transplanted patients. J. Immunol.180(12), 8455–8460 (2008).
   PubMedGoogle Scholar
• Wootla B, Lacroix-Desmazes S, Warrington AE, Bieber AJ, Kaveri SV, Rodriguez M. Autoantibodies with enzymatic properties in human autoimmune diseases. J. Autoimmun.37(2), 144–150 (2011).
   PubMedGoogle Scholar
• Wootla B, Denic A, Keegan BM et al. Evidence for the role of B cells and immunoglobulins in the pathogenesis of multiple sclerosis. Neurol. Res. Int.2011, 780712 (2011).
   PubMedGoogle Scholar
• Rodriguez M, Lennon VA, Benveniste EN, Merrill JE. Remyelination by oligodendrocytes stimulated by antiserum to spinal cord. J. Neuropathol. Exp. Neurol.46(1), 84–95 (1987).
   PubMed Web of Science ®Google Scholar
• Howe CL, Bieber AJ, Warrington AE, Pease LR, Rodriguez M. Antiapoptotic signaling by a remyelination-promoting human antimyelin antibody. Neurobiol. Dis.15(1), 120–131 (2004).
   PubMed Web of Science ®Google Scholar
• Miller DJ, Rodriguez M. A monoclonal autoantibody that promotes central nervous system remyelination in a model of multiple sclerosis is a natural autoantibody encoded by germline immunoglobulin genes. J. Immunol.154(5), 2460–2469 (1995).
   PubMed Web of Science ®Google Scholar
• Warrington AE, Asakura K, Bieber AJ et al. Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis. Proc. Natl Acad. Sci. USA97(12), 6820–6825 (2000).
   PubMed Web of Science ®Google Scholar
• Mitsunaga Y, Ciric B, Van Keulen V et al. Direct evidence that a human antibody derived from patient serum can promote myelin repair in a mouse model of chronic-progressive demyelinating disease. FASEB J.16(10), 1325–1327 (2002).
   PubMed Web of Science ®Google Scholar
• Warrington AE, Bieber AJ, Van Keulen V, Ciric B, Pease LR, Rodriguez M. Neuron-binding human monoclonal antibodies support central nervous system neurite extension. J. Neuropathol. Exp. Neurol.63(5), 461–473 (2004).
   PubMed Web of Science ®Google Scholar
• Van Keulen VP, Ciric B, Radhakrishnan S et al. Immunomodulation using the recombinant monoclonal human B7-DC cross-linking antibody rHIgM12. Clin. Exp. Immunol.143(2), 314–321 (2006).
   PubMedGoogle Scholar
• Xu X, Warrington AE, Wright BR et al. A human IgM signals axon outgrowth: coupling lipid raft to microtubules. J. Neurochem.119(1), 100–112 (2011).
   PubMedGoogle Scholar
• Denic A, Macura SI, Warrington AE et al. A single dose of neuron-binding human monoclonal antibody improves spontaneous activity in a murine model of demyelination. PLoS One6(10), e26001 (2011).
   PubMedGoogle Scholar
• Casali P, Schettino EW. Structure and function of natural antibodies. Curr. Top Microbiol. Immunol.210, 167–179 (1996).
   PubMed Web of Science ®Google Scholar
• Baumgarth N. The double life of a B-1 cell: self-reactivity selects for protective effector functions. Nat. Rev. Immunol.11(1), 34–46 (2011).
   PubMed Web of Science ®Google Scholar
• Warrington AE, Van Keulen V, Pease LR, Rodriguez M. Naturally occurring antibodies as therapeutics for neurologic disease: can human monoclonal IgMs replace the limited resource IVIg? In: Naturally Occurring Antibodies (NAbs). Lutz HU (Ed.). Landes Bioscience and Springer Science + Business Media, NY, USA (2011).
   Google Scholar
• Watzlawik J, Holicky E, Edberg DD et al. Human remyelination promoting antibody inhibits apoptotic signaling and differentiation through Lyn kinase in primary rat oligodendrocytes. Glia58(15), 1782–1793 (2010).
   PubMed Web of Science ®Google Scholar
• Popovich PG, Longbrake EE. Can the immune system be harnessed to repair the CNS? Nat. Rev. Neurosci.9(6), 481–493 (2008).
   PubMedGoogle Scholar
• Cao Q, He Q, Wang Y et al. Transplantation of ciliary neurotrophic factor-expressing adult oligodendrocyte precursor cells promotes remyelination and functional recovery after spinal cord injury. J. Neurosci.30(8), 2989–3001 (2010).
   PubMed Web of Science ®Google Scholar
• Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS study: a randomized controlled trial. Alteplase thrombolysis for acute noninterventional therapy in ischemic stroke. JAMA282(21), 2019–2026 (1999).
   PubMed Web of Science ®Google Scholar
• Cudkowicz ME, Katz J, Moore DH et al. Toward more efficient clinical trials for amyotrophic lateral sclerosis. Amyotroph Lateral Scler.11(3), 259–265 (2010).
   PubMed Web of Science ®Google Scholar
• Gurney ME, Fleck TJ, Himes CS, Hall ED. Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis. Neurology50(1), 62–66 (1998).
   PubMed Web of Science ®Google Scholar
• Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst. Rev.1, CD001447 (2007).
   Google Scholar
• Coles AJ, Fox E, Vladic A et al. Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. Lancet Neurol.10(4), 338–348 (2011).
   PubMed Web of Science ®Google Scholar
• Fox EJ, Sullivan HC, Gazda SK et al. A single-arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosis. Eur. J. Neurol.19(2), 307–311 (2012).
   PubMed Web of Science ®Google Scholar
• Bielekova B, Richert N, Herman ML et al. Intrathecal effects of daclizumab treatment of multiple sclerosis. Neurology77(21), 1877–1886 (2011).
   PubMed Web of Science ®Google Scholar
• Brown BA, Torabi M. Incidence of infusion-associated reactions with rituximab for treating multiple sclerosis: a retrospective analysis of patients treated at a US centre. Drug Saf.34(2), 117–123 (2011).
   PubMed Web of Science ®Google Scholar
• Mi S, Lee X, Shao Z et al. LINGO-1 is a component of the Nogo-66 receptor/p75 signaling complex. Nat. Neurosci.7(3), 221–228 (2004).
   PubMed Web of Science ®Google Scholar
• Mi S, Miller RH, Lee X et al. LINGO-1 negatively regulates myelination by oligodendrocytes. Nat. Neurosci.8(6), 745–751 (2005).
   PubMed Web of Science ®Google Scholar
• Mi S, Hu B, Hahm K et al. LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nat. Med.13(10), 1228–1233 (2007).
   PubMed Web of Science ®Google Scholar
• Warrington AE, Bieber AJ, Ciric B, Pease LR, Van Keulen V, Rodriguez M. A recombinant human IgM promotes myelin repair after a single, very low dose. J. Neurosci. Res.85(5), 967–976 (2007).
   PubMed Web of Science ®Google Scholar
• Banerjee S, Bhat MA. Neuron-glial interactions in blood-brain barrier formation. Annu. Rev. Neurosci.30, 235–258 (2007).
   PubMed Web of Science ®Google Scholar
• Steinmetz MP, Horn KP, Tom VJ et al. Chronic enhancement of the intrinsic growth capacity of sensory neurons combined with the degradation of inhibitory proteoglycans allows functional regeneration of sensory axons through the dorsal root entry zone in the mammalian spinal cord. J. Neurosci.25(35), 8066–8076 (2005).
   PubMed Web of Science ®Google Scholar
• Barritt AW, Davies M, Marchand F et al. Chondroitinase ABC promotes sprouting of intact and injured spinal systems after spinal cord injury. J. Neurosci.26(42), 10856–10867 (2006).
   PubMed Web of Science ®Google Scholar
• Santoro SW, Joyce GF. A general purpose RNA-cleaving DNA enzyme. Proc. Natl Acad. Sci. USA94(9), 4262–4266 (1997).
   PubMed Web of Science ®Google Scholar
• Grimpe B, Silver J. A novel DNA enzyme reduces glycosaminoglycan chains in the glial scar and allows microtransplanted dorsal root ganglia axons to regenerate beyond lesions in the spinal cord. J. Neurosci.24(6), 1393–1397 (2004).
   PubMed Web of Science ®Google Scholar
• Park KK, Liu K, Hu Y et al. Promoting axon regeneration in the adult CNS by modulation of the PTEN/mTOR pathway. Science322(5903), 963–966 (2008).
   PubMed Web of Science ®Google Scholar
• McDonald JW, Liu XZ, Qu Y et al. Transplanted embryonic stem cells survive, differentiate and promote recovery in injured rat spinal cord. Nat. Med.5(12), 1410–1412 (1999).
   PubMed Web of Science ®Google Scholar
• Toda H, Takahashi J, Iwakami N et al. Grafting neural stem cells improved the impaired spatial recognition in ischemic rats. Neurosci. Lett.316(1), 9–12 (2001).
   PubMed Web of Science ®Google Scholar
• Chen J, Li Y, Wang L et al. Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats. Stroke32(4), 1005–1011 (2001).
   PubMed Web of Science ®Google Scholar
• Munoz-Elias G, Marcus AJ, Coyne TM, Woodbury D, Black IB. Adult bone marrow stromal cells in the embryonic brain: engraftment, migration, differentiation, and long-term survival. J. Neurosci.24(19), 4585–4595 (2004).
   PubMed Web of Science ®Google Scholar
• Sykova E, Homola A, Mazanec R et al. Autologous bone marrow transplantation in patients with subacute and chronic spinal cord injury. Cell Transplant.15(8–9), 675–687 (2006).
   PubMed Web of Science ®Google Scholar
• Arvidsson A, Collin T, Kirik D, Kokaia Z, Lindvall O. Neuronal replacement from endogenous precursors in the adult brain after stroke. Nat. Med.8(9), 963–970 (2002).
   PubMed Web of Science ®Google Scholar
• Ming GL, Song H. Adult neurogenesis in the mammalian central nervous system. Annu. Rev. Neurosci.28, 223–250 (2005).
   PubMed Web of Science ®Google Scholar
• Verdu E, Garcia-Alias G, Fores J, Lopez-Vales R, Navarro X. Olfactory ensheathing cells transplanted in lesioned spinal cord prevent loss of spinal cord parenchyma and promote functional recovery. Glia42(3), 275–286 (2003).
   PubMedGoogle Scholar
• Kawada H, Takizawa S, Takanashi T et al. Administration of hematopoietic cytokines in the subacute phase after cerebral infarction is effective for functional recovery facilitating proliferation of intrinsic neural stem/progenitor cells and transition of bone marrow-derived neuronal cells. Circulation113(5), 701–710 (2006).
   PubMed Web of Science ®Google Scholar
• Erdo F, Buhrle C, Blunk J et al. Host-dependent tumorigenesis of embryonic stem cell transplantation in experimental stroke. J. Cereb. Blood Flow Metab.23(7), 780–785 (2003).
   PubMed Web of Science ®Google Scholar
• Case LC, Tessier-Lavigne M. Regeneration of the adult central nervous system. Curr. Biol.15(18), R749–R753 (2005).
   PubMed Web of Science ®Google Scholar
• Souan ML, Geffard M, Vieillemaringe J, Lebrun-Grandie P, Orgogozo JM. Anti-acetylcholine antibodies and the pathogenesis of myasthenia gravis. Ann. NY Acad. Sci.505, 423–438 (1987).
   PubMedGoogle Scholar
• Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J. Exp. Med.202(4), 473–477 (2005).
   PubMed Web of Science ®Google Scholar
• Motomura M, Lang B, Johnston I, Palace J, Vincent A, Newsom-Davis J. Incidence of serum anti-P/O-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. J. Neurol. Sci.147(1), 35–42 (1997).
   PubMed Web of Science ®Google Scholar
• Stich O, Klages E, Bischler P et al. SOX1 antibodies in sera from patients with paraneoplastic neurological syndromes. Acta Neurol. Scand. (2011).
   PubMedGoogle Scholar
• Lardone RD, Yuki N, Odaka M, Daniotti JL, Irazoqui FJ, Nores GA. Anti-GM1 IgG antibodies in Guillain-Barre syndrome: fine specificity is associated with disease severity. J. Neurol. Neurosurg. Psychiatry81(6), 629–633 (2010).
   PubMed Web of Science ®Google Scholar
• Pittock SJ, Lucchinetti CF, Lennon VA. Anti-neuronal nuclear autoantibody Type 2: paraneoplastic accompaniments. Ann. Neurol.53(5), 580–587 (2003).
   PubMed Web of Science ®Google Scholar
• Hoffmann LA, Jarius S, Pellkofer HL et al. Anti-Ma and anti-Ta associated paraneoplastic neurological syndromes: 22 newly diagnosed patients and review of previous cases. J. Neurol. Neurosurg. Psychiatry79(7), 767–773 (2008).
   PubMedGoogle Scholar
• Dalmau J, Graus F, Villarejo A et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain127(Pt 8), 1831–1844 (2004).
   PubMed Web of Science ®Google Scholar
• Pittock SJ, Lucchinetti CF, Parisi JE et al. Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann. Neurol.58(1), 96–107 (2005).
   PubMed Web of Science ®Google Scholar
• Graus F, Dalmau J, Valldeoriola F et al. Immunological characterization of a neuronal antibody (anti-Tr) associated with paraneoplastic cerebellar degeneration and Hodgkin’s disease. J. Neuroimmunol.74(1–2), 55–61 (1997).
   PubMed Web of Science ®Google Scholar
• Peterson K, Rosenblum MK, Kotanides H, Posner JB. Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology42(10), 1931–1937 (1992).
   PubMed Web of Science ®Google Scholar
• Graus F, Keime-Guibert F, Rene R et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain124(Pt 6), 1138–1148 (2001).
   PubMed Web of Science ®Google Scholar
• Adamus G, Guy J, Schmied JL, Arendt A, Hargrave PA. Role of anti-recoverin autoantibodies in cancer-associated retinopathy. Invest. Ophthalmol. Vis. Sci.34(9), 2626–2633 (1993).
   PubMed Web of Science ®Google Scholar
• Shiraga S, Adamus G. Mechanism of CAR syndrome: anti-recoverin antibodies are the inducers of retinal cell apoptotic death via the caspase 9- and caspase 3-dependent pathway. J. Neuroimmunol.132(1–2), 72–82 (2002).
   PubMed Web of Science ®Google Scholar
• Honnorat J, Antoine JC, Derrington E, Aguera M, Belin MF. Antibodies to a subpopulation of glial cells and a 66 kDa developmental protein in patients with paraneoplastic neurological syndromes. J. Neurol. Neurosurg. Psychiatry61(3), 270–278 (1996).
   PubMed Web of Science ®Google Scholar
• Eisenbarth GS, Walsh FS, Nirenberg M. Monoclonal antibody to a plasma membrane antigen of neurons. Proc. Natl Acad. Sci. USA76(10), 4913–4917 (1979).
   PubMed Web of Science ®Google Scholar
• Inoko E, Nishiura Y, Tanaka H et al. Developmental stage-dependent expression of an α2,8-trisialic acid unit on glycoproteins in mouse brain. Glycobiology20(7), 916–928 (2010).
   PubMed Web of Science ®Google Scholar
• Bansal R, Warrington AE, Gard AL, Ranscht B, Pfeiffer SE. Multiple and novel specificities of monoclonal antibodies O1, O4, and R-mAb used in the analysis of oligodendrocyte development. J. Neurosci. Res.24(4), 548–557 (1989).
   PubMedGoogle Scholar